[Major Events] Guoen Technology (02768) will conduct its IPO from January 27 to January 30, with an expected listing date of February 4. Ming Ming Is Very Busy (01768) announced its Hong Kong public offering was oversubscribed by 1,899.49 times, with a final offer price of HKD 236.6 per share. Weichuan Holdings (03393) proposed the spin-off of Weiyuan Energy and its independent listing on the Main Board of the Hong Kong Stock Exchange. Anta Sports (02020) plans to acquire approximately 29.06% of the equity in PUMA SE for about EUR 1.506 billion. Insilico Medicine (03696) entered into a drug R&D collaboration with Qilu Pharmaceutical valued at over HKD 931 million, aiming to accelerate the development of innovative therapies for cardiovascular and metabolic diseases. Huajian Medical (01931) announced its subsidiary successfully developed a dual-platform testing solution for the Nipah virus, alongside an upgrade to the group's AI healthcare strategy.

[Financial Data] China Merchants Securities (06099) reported an attributable net profit of RMB 12.3 billion for the 2025 fiscal year, representing a year-on-year increase of 18.43%. Haitong Hengxin (01905) released its 2025 performance forecast, indicating an annual profit of RMB 1.425 billion, a decrease of 5.8% compared to the previous year. Guotai Haitong (02611) issued a positive profit alert, expecting an annual attributable net profit in the range of approximately RMB 27.533 billion to RMB 28.006 billion, marking a significant increase of 111% to 115% year-on-year. Shenwan Hongyuan (06806) also issued a positive profit alert, anticipating an annual attributable net profit between RMB 9.1 billion and RMB 10.1 billion, which translates to a growth rate of 74.64% to 93.83% compared to the prior year. SITC International (01308) projected its annual profit attributable to equity shareholders to be between approximately USD 1.2 billion and USD 1.23 billion, indicating an increase of about 16.0% to 18.9% year-on-year. Orient Securities (03958) estimated its 2025 attributable net profit to be RMB 5.62 billion, a substantial increase of 67.8% year-on-year. Ganfeng Lithium (01772) forecasted a turnaround to profitability for 2025, with an expected attributable net profit ranging from RMB 1.1 billion to RMB 1.65 billion. CanSino Biologics (06185) anticipated achieving an attributable net profit between RMB 24.5 million and RMB 29 million for the 2025 fiscal year, also representing a turnaround from a loss to a profit. COSCO SHIPPING Ports (02669) issued a profit warning, expecting its profit attributable to equity shareholders for 2025 to decrease by 9-10% year-on-year. China Traditional Chinese Medicine (00570) forecasted a net loss of approximately RMB 350 million to RMB 500 million for the 2025 fiscal year.

[Financing Activities] China Ruyi (00136) proposed the issuance of HKD 2.574 billion zero-coupon convertible bonds due in 2027. Conant Optical (02276) plans to place 27 million shares at a discount of approximately 11.1%, aiming to raise net proceeds of about HKD 1.4 billion. Hansoh Pharma (03692) recommended the issuance of HKD 4.68 billion zero-coupon convertible bonds due in 2033. China Securities (06066) intends to issue corporate bonds with a total value not exceeding RMB 1.5 billion. China Vanke (02202) is set to receive a loan of up to RMB 2.36 billion from its major shareholder, Shenzhen Metro Group.